Managing Takayasu’s arteritis requires a careful balance between controlling inflammation and preventing serious damage to the arteries. This rare condition can progress silently for years, making early recognition and treatment crucial for protecting the heart, brain, and other vital organs from the consequences of restricted blood flow.

How Treatment Approaches Protect Arteries and Improve Quality of Life

The main goal when treating Takayasu’s arteritis is to reduce the inflammation that attacks the walls of large arteries, particularly the aorta (the main blood vessel leaving the heart) and its branches. Without treatment, this inflammation causes the arteries to narrow, stiffen, or weaken, which can lead to life-threatening complications such as heart attack, stroke, or kidney damage. Treatment aims to stop this progression, manage symptoms like pain and fatigue, and help people maintain their daily activities and independence.^[1]

Because Takayasu’s arteritis is a chronic condition that often affects young women, treatment plans need to be sustainable over many years. Doctors consider not only how to control the disease but also how to minimize the long-term side effects of medications. The approach varies depending on how active the inflammation is, which arteries are affected, and whether complications like high blood pressure or narrowed vessels have already developed.^[2]

Not every person with Takayasu’s arteritis experiences symptoms in the early stages, and some may have mild disease that doesn’t require aggressive treatment. However, most people need medications to control inflammation in their arteries and prevent the disease from worsening. Even when treatment is successful, the condition can return, so ongoing monitoring is essential. The alternating pattern of active disease and periods of calm, called remission, means that therapy often needs adjustment over time.^[1]

Standard Medications Used to Control Inflammation

Corticosteroids, specifically prednisone, are the foundation of treatment for Takayasu’s arteritis. These powerful anti-inflammatory drugs work by suppressing the immune system’s attack on artery walls. Doctors typically start with a dose of 0.5 to 1 milligram per kilogram of body weight daily. This initial high dose is designed to quickly bring the inflammation under control during the active phase of the disease.^[11]

The goal is to gradually reduce the steroid dose over time while keeping the disease inactive. Treatment guidelines suggest lowering the dose to less than 20 milligrams per day by the end of the third month, and to less than 0.1 milligram per kilogram daily by the sixth month. If the disease remains quiet, doctors may consider stopping steroids completely after 24 months of treatment, though this decision requires careful monitoring to ensure the adrenal glands are functioning properly.^[13]

Long-term steroid use comes with significant risks. People taking prednisone for extended periods may develop osteoporosis (weakening of the bones), diabetes, weight gain, mood changes, and increased vulnerability to infections. To protect bone health, doctors prescribe calcium and vitamin D supplements alongside steroids. Regular monitoring of blood sugar, weight, and metabolic health is important throughout treatment.^[13]

Many people with Takayasu’s arteritis need additional medications beyond steroids. These are called immunosuppressants or steroid-sparing agents because they help control the disease while allowing doctors to reduce or stop corticosteroids. Common immunosuppressants include methotrexate, azathioprine, and mycophenolate. These drugs work by dampening different parts of the immune response that drive arterial inflammation.^[5]

Another class of medications gaining prominence in Takayasu’s arteritis treatment are biologics, which are engineered proteins that target specific molecules in the immune system. Tumor necrosis factor (TNF) blockers such as adalimumab and infliximab have been used successfully in people who don’t respond adequately to steroids and traditional immunosuppressants. These medications are given by injection or infusion and work by blocking a protein that drives inflammation throughout the body.^[5]

Low-dose aspirin is often prescribed to people with Takayasu’s arteritis, typically 75 to 300 milligrams daily, unless there’s a reason they shouldn’t take it. Aspirin helps prevent blood clots from forming in narrowed arteries, which reduces the risk of stroke and heart attack. This is particularly important because the damaged, irregular artery walls in Takayasu’s arteritis are more prone to clot formation.^[13]

Managing high blood pressure is another critical component of treatment. Many people with Takayasu’s arteritis develop hypertension due to narrowing of the arteries that supply the kidneys, a condition called renal artery stenosis. Various blood pressure medications may be needed, and treatment should start as soon as high blood pressure is detected to protect the kidneys, heart, and brain from further damage.^[5]

In some cases, surgery becomes necessary to address severely narrowed or blocked arteries. Procedures include angioplasty (opening narrowed vessels with a balloon), stenting (placing a tube to keep arteries open), or bypass surgery (creating new paths for blood to flow around blockages). These interventions are typically performed when the disease is inactive to reduce the risk of complications and improve outcomes.^[5]

Innovative Therapies Being Studied in Clinical Trials

Researchers are actively investigating new treatment options for Takayasu’s arteritis through clinical trials around the world, including in the United States, Europe, and Asia. One of the most promising approaches involves a medication called tocilizumab, which blocks interleukin-6 (IL-6), a protein that plays a major role in the inflammatory process affecting large blood vessels.^[11]

Tocilizumab is a humanized monoclonal antibody that targets the IL-6 receptor. Evidence from multiple studies suggests that IL-6 is particularly important in large-vessel vasculitis like Takayasu’s arteritis. When this pathway is blocked, inflammation in the artery walls decreases, allowing the disease to become less active. Case reports and observational studies have shown that tocilizumab can help people who haven’t responded well to standard treatments, including those who failed to improve with TNF inhibitors.^[11]

A significant clinical trial called the TAKT trial tested whether tocilizumab could help people reduce their steroid use while keeping the disease under control. This was a Phase III randomized, double-blind, placebo-controlled study, which is considered the gold standard for testing whether treatments work. The trial enrolled patients whose Takayasu’s arteritis had gone into remission with steroids, and then tested whether adding tocilizumab allowed them to stay in remission better than placebo. While the primary endpoint wasn’t met, the results suggested tocilizumab had favorable effects and was safe.^[11]

An open-label extension of the TAKT trial followed 28 patients who received tocilizumab 162 milligrams once weekly for 96 weeks. This longer study provided evidence that tocilizumab helped reduce steroid requirements and improved how patients felt overall, without raising new safety concerns. These findings are encouraging for people struggling with steroid side effects or disease that doesn’t respond to conventional therapy.^[11]

Another avenue of research involves rituximab, a medication that depletes B-cells, a type of white blood cell involved in immune responses. Rituximab is a chimeric antibody that binds to CD20, a protein found on B-cell surfaces. Although Takayasu’s arteritis is not thought to be primarily driven by antibodies (which B-cells produce), these cells appear to contribute to inflammation through other mechanisms. Studies have shown that rituximab can improve clinical signs and symptoms in some people with Takayasu’s arteritis.^[11]

Clinical trials are also examining combinations of different immunosuppressive medications to find regimens that control disease while minimizing side effects. Researchers are comparing outcomes between tocilizumab and TNF-alpha inhibitors, looking at rates of remission, blood vessel stability on imaging tests, and adverse events. A meta-analysis of six studies found similar effectiveness between these two classes of biologics, which helps doctors understand they have multiple options when conventional treatments aren’t sufficient.^[11]

The trial landscape continues to evolve, with researchers investigating not just which medications work, but how to measure disease activity accurately. Blood tests like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are commonly used to monitor inflammation, but they don’t always reflect what’s happening in the artery walls. Advanced imaging techniques, including magnetic resonance imaging (MRI) and computed tomography (CT) angiography, are being refined to better detect active inflammation and track treatment response.^[9]

Patients interested in participating in clinical trials can discuss options with their rheumatologist or vascular specialist. Eligibility criteria vary by study but often include factors such as disease activity level, previous treatments tried, and overall health status. Participating in research not only provides access to potentially beneficial new therapies but also contributes to advancing knowledge that may help future patients with Takayasu’s arteritis.

Most common treatment methods

• Corticosteroid therapy
  • Prednisone at initial doses of 0.5 to 1 mg/kg daily to reduce arterial inflammation
  • Gradual dose reduction over months to minimize side effects like osteoporosis and weight gain
  • Calcium and vitamin D supplementation to protect bone health during long-term use
  • Goal to reach low doses or discontinuation after 24 months if disease remains inactive
• Immunosuppressive medications
  • Methotrexate to control immune system activity and allow steroid dose reduction
  • Azathioprine as an alternative immunosuppressant to maintain disease remission
  • Mycophenolate for people who don’t respond to other immunosuppressive drugs
  • Regular monitoring of blood counts and liver function while on these medications
• Biologic agents
  • Tocilizumab, which blocks IL-6 receptors to reduce inflammation in artery walls
  • TNF inhibitors like adalimumab and infliximab for refractory disease
  • Rituximab to deplete B-cells in cases that don’t respond to standard therapy
  • Given by injection or infusion with monitoring for infection risk
• Antiplatelet therapy
  • Low-dose aspirin (75-300 mg daily) to prevent blood clots in narrowed arteries
  • Reduces risk of stroke and heart attack in people with vascular narrowing
  • Continued unless specific contraindications exist
• Blood pressure management
  • Various antihypertensive medications tailored to individual needs
  • Essential for people with renal artery stenosis causing high blood pressure
  • Blood pressure measured in legs if arm arteries are blocked
• Surgical interventions
  • Angioplasty and stenting to open narrowed arteries and restore blood flow
  • Bypass surgery to redirect blood around severely blocked vessels
  • Performed when disease is inactive to reduce complications